Miniature, Portable, Device to Detect and Monitor Coagulopathy

Award Information
Agency: Department of Defense
Branch: Navy
Contract: N00014-10-M-0360
Agency Tracking Number: N10A-043-0364
Amount: $69,992.00
Phase: Phase I
Program: STTR
Awards Year: 2010
Solicitation Year: 2010
Solicitation Topic Code: N10A-T043
Solicitation Number: 2010.A
Small Business Information
HemoSonics, LLC
745 Walker Square, Suite 3C, Charlottesville, VA, 22903
DUNS: 193921041
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Francesco Viola
 VP Engineering and Techno
 (434) 409-6281
 fviola@hemosonics.com
Business Contact
 William Walker
Title: President
Phone: (434) 962-2269
Email: bwalker@hemosonics.com
Research Institution
 The University of Virginia
 Michael G Glasgow
 OSP 1001 North Emmet Street
PO Box 400195
Charlottesville, VA, 22904
 (434) 924-4270
 Nonprofit college or university
Abstract
Trauma is a leading cause of both military and civilian mortality, accounting for roughly 10% of all deaths worldwide. Coagulopathy (disturbance of the physiologic balance between bleeding and clotting) is observed in 25% to 36% of trauma patients and significantly increases mortality. Trauma-related coagulopathy typically involves dysfunction or depletion of coagulation factors, platelets, fibrinogen, and fibrinolysis. Each of these defects requires specific treatment to correct, while improper treatment consumes time, money, and limited resources, and worsens outcomes. Proper trauma treatment requires the rapid assessment of hemostatic state. The ideal test is performed at the point of care, is robust to environmental vibration, takes only a few minutes to perform, specifies the exact hemostatic defect(s), is easy to use, and presents easy to interpret results. Unfortunately, no commercially available test or combination of tests meets these criteria. Under this proposal HemoSonics will test the applicability of its proprietary Sonorheometry technology to assess coagulopathy at the point of care. We will assess potential technical barriers and validate our approach to this critical health care problem. Success in Phase I will pave the way to a Phase II award and product commercialization.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government